DHC (Diversified Healthcare Trust) Research & Development: $0 Mil (TTM As of Mar. 2026)


DHC Diversified Healthcare Trust DHC
56 GF Score
Price $9.37
GF Value $3.20
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Diversified Healthcare Trust Research & Development?

Diversified Healthcare Trust DHC +2.52% 56 Research & Development is $0 Mil as of Mar. 2026. GuruFocus rates DHC with a GF Score™ of 56/100 and a GF Value™ of $3.20 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Diversified Healthcare Trust's Research & Development for the three months ended in Mar. 2026 was $0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $0 Mil.

Diversified Healthcare Trust  (NAS:DHC) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Diversified Healthcare Trust Research & Development Related Terms

Diversified Healthcare Trust Research & Development Historical Data

* Premium members only.

The historical data trend for Diversified Healthcare Trust's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diversified Healthcare Trust Research & Development Chart

Diversified Healthcare Trust Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Diversified Healthcare Trust Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
DHC
56GF Score
Diversified Healthcare Trust DHC
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Diversified Healthcare Trust Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $0 Mil mean?
Diversified Healthcare Trust (DHC) has a Research & Development of $0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Diversified Healthcare Trust and its competitors.
Is Diversified Healthcare Trust's Research & Development too high?
Diversified Healthcare Trust's current Research & Development is $0 Mil. Overall, Diversified Healthcare Trust has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Diversified Healthcare Trust's Research & Development compare to LTC and SILA?
Diversified Healthcare Trust's Research & Development of $0 Mil can be compared against companies in the REITs industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a REITs company?
A good Research & Development depends on the REITs industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Diversified Healthcare Trust and its competitors. Diversified Healthcare Trust's current Research & Development is $0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diversified Healthcare Trust stock overvalued right now?
Based on GuruFocus' analysis, Diversified Healthcare Trust (DHC) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.20, compared to a current price of $9.37 — trading 192.8% above its estimated fair value. The current Research & Development is $0 Mil. Diversified Healthcare Trust's overall GF Score™ is 56/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Diversified Healthcare Trust (DHC), the current Research & Development is $0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Diversified Healthcare Trust (DHC) Overvalued in 2026?

Based on GuruFocus' analysis, Diversified Healthcare Trust stock appears to be overvalued. The current stock price of $9.37 is trading 192.8% above its estimated GF Value™ of $3.20. GuruFocus considers Diversified Healthcare Trust to be Significantly Overvalued.

Key valuation signals for DHC:

  • Research & Development: $0 Mil
  • GF Value™: $3.20 vs. price of $9.37 (192.8% above fair value)
  • GF Score™: 56/100 with 7 warning signs

No single metric tells the full story. See the DHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Diversified Healthcare Trust Business Description

Industry Real EstateREITs
Other Exchanges SNF:Germany
Address 255 Washington Street, Suite 300, Two Newton Place, Newton, MA, USA, 02458-1634
Diversified Healthcare Trust is a real estate investment trust that focuses on healthcare-related properties, including life science estates, medical offices, and senior living communities. It acquires and owns properties and is engaged in the development and implementation of medical services and technologies. The company has two reportable segments: SHOP (Senior Housing Operating Portfolio) and Medical Office and Life Science Portfolio. The SHOP segment includes managed senior living communities providing residential living and care services. The Medical Office and Life Science Portfolio segment consists of properties leased to medical providers and biotechnology laboratories. It generates the majority of its revenue from the SHOP segment.
56GF Score

Get the complete analysis for DHC

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.37
Price
$3.20
GF Value